A multicentre, multinational, randomized, placebo‐controlled, double‐blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin ( <scp>LC15</scp> ‐0444) in patients with type 2 diabetes

201251 citationsJournal Article

Authors

This study showed the efficacy and safety of gemigliptin 50 mg administered once daily as a monotherapy for type 2 diabetes patients.

Good health and well-being

Published in: Diabetes Obesity and Metabolism

Volume 15, Issue 5, pp. 410-416

Field-Weighted Citation Impact: 3.23